Life Sciences

  • February 20, 2026

    Dallas Jury Finds Ex-NFL Player Ran $328M Medicare Scheme

    A federal jury in Dallas has found that former NFL player and Texas laboratory owner Keith Gray orchestrated a $328 million fraud scheme involving billing for cardiovascular genetic testing, federal prosecutors said Thursday.

  • February 20, 2026

    Fertility Doctors Beat Patient's Embryo Loss Case

    A Connecticut woman waited too long to sue her fertility doctors over the loss of her frozen embryos after treatments in 2005 and 2006, a state court judge ruled Thursday, granting judgment to the doctors.

  • February 20, 2026

    Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP

    The Federal Circuit on Friday saved Regenxbio and the University of Pennsylvania's gene therapy patent, finding that splicing together genes from different organisms results in a molecule that is "markedly different from anything occurring in nature," rendering the therapy patent eligible. 

  • February 20, 2026

    Merck Wants Out Of Ex-Workers' Wage, ADA Suit

    Merck urged a North Carolina federal court on Friday to dismiss a former manufacturing facility employee's proposed class and collective action, arguing federal wage law bars his state overtime claim and that he failed to link his firing to sleep apnea.

  • February 20, 2026

    Chinese Chemical Imports Evading Duties, Commerce Says

    The U.S. Department of Commerce determined Friday that Chinese imports of a water treatment chemical into the U.S. are skirting antidumping and countervailing duties against such products after a U.S. company accused the countrywide industry of making misleading "minor" alterations.

  • February 20, 2026

    Beasley Allen Can't Pause NJ Talc DQ Order, Judge Rules

    The Beasley Allen Law Firm can't delay an order disqualifying it from representing hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder while it seeks review from the New Jersey Supreme Court, a state judge ruled on Friday.

  • February 20, 2026

    Judge Says Texas Can't Enforce Optometry Anti-Steering Law

    A Texas federal judge on Friday blocked the state from enforcing an anti-steering law that banned managed care plans from telling insureds about optometrists who offer cheaper options, saying that the law violated protected commercial speech. 

  • February 20, 2026

    US Hits Pill Capsules From 4 Countries With Duty Orders

    The U.S. Department of Commerce hit empty pill capsules from China, India, Brazil and Vietnam imported into the U.S. with antidumping and countervailing duty orders, with some of the rates stretching higher than 77%.

  • February 20, 2026

    Taxation With Representation: Freshfields, Simpson Thacher

    In this week's Taxation With Representation, science and technology company Danaher Corp. acquires medical technology company Masimo Corp., Covetrus merges with a unit of fellow animal health technology company Cencora, and private equity firm Leonard Green & Partners LP buys outstanding Mister Car Wash Inc. shares not already owned by LGP affiliates.

  • February 19, 2026

    Judge Denies Mylan And Aurobindo's Bid To Escape Trial

    A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.

  • February 19, 2026

    Texas Suit Says Sanofi Paid Kickbacks For Prescriptions

    Texas Attorney General Ken Paxton sued Sanofi-Aventis US LLC in state court Thursday, accusing the pharmaceutical company of paying kickbacks to providers so they would prescribe Sanofi's drugs.

  • February 19, 2026

    Justices Urged To Bar Passive Infringement For Skinny Labels

    The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme Court in a case over so-called skinny labels.

  • February 19, 2026

    Judge Affirms Literal Infringement In Ravgen's $57M Jury Win

    A Texas federal judge has upheld a jury's finding that genetic testing company Natera Inc. committed literal infringement of a patent held by Ravgen Inc., but said Ravgen's expert testimony wasn't enough to support the jury's finding of infringement under the doctrine of equivalents.

  • February 19, 2026

    Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules

    A coalition of 21 Republican state attorneys general, led by Nebraska, urged a federal judge to grant Louisiana's bid to block the U.S. Food and Drug Administration's 2023 rules easing access to the abortion drug mifepristone, arguing that the policy undermines states' authority to enforce their own abortion laws and imposes a "pocketbook injury" on states.

  • February 19, 2026

    She Has A Point: Dechert's Kassie Helm

    Kassie Helm, co-chair of Dechert LLP's global intellectual property group and head of its IP litigation group, is "unquestionably one of the leading lights of her generation," according to Morrison Foerster LLP partner Daralyn Durie, who praised Helm for her work as opposing counsel in a new series celebrating women litigators.

  • February 19, 2026

    Squires Accepts 8 PTAB Cases, Walks Back 7 Merits Referrals

    A bulk summary order from U.S. Patent and Trademark Office Director John Squires granted eight petitions for America Invents Act patent challenges while denying 14 others, including seven that he had previously accepted for merits-based review.

  • February 19, 2026

    Pharma Group Asks 1st Circ. To Ax RI's 340B Drug Price Law

    A pharmaceutical trade group has urged the First Circuit to overturn a district court's order siding with a Rhode Island law that bars drug manufacturers from blocking hospitals and clinics from contracting with outside pharmacies to dispense discounted drugs under the federal 340B Discount Drug Program. 

  • February 19, 2026

    Hims & Hers Buying Eucalyptus For Up To $1.15B

    Wellness platform Hims & Hers Health Inc. said Thursday it has agreed to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion.

  • February 19, 2026

    Scientist Must Give Splenda Maker Emails With In-House Attys

    A scientist battling a lawsuit by the maker of Splenda over her research linking the artificial sweetener to cancer-causing chemicals must turn over emails with her employer's in-house counsel, a North Carolina magistrate judge ruled, finding they are not protected by privilege.

  • February 19, 2026

    Fed. Circ. Won't Revive Corcept's Drug Patent Feud

    The Federal Circuit on Thursday declined to revive a case from Corcept Therapeutics Inc. in which it accused Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying a district judge didn't make a clear error in ruling Corcept hadn't shown any infringement.

  • February 19, 2026

    Harvard Docs Get Censored Articles Permanently Restored

    The Trump administration agreed to maintain the court-ordered restoration of articles penned by Harvard Medical School researchers that contained references to the LGBTQ+ community after they had previously been scrubbed from a government-hosted website.

  • February 19, 2026

    AstraZeneca Prevails In Whistleblower Suit 9th Circ. Revived

    An Oregon federal judge tossed a former AstraZeneca sales manager's whistleblower claims that she was fired for accusing a colleague of promoting off-label drugs, in a case that took a trip to the Ninth Circuit and back.

  • February 19, 2026

    Trump Orders Weedkiller Glyphosate Production Hike

    President Donald Trump issued an executive order late Wednesday aimed at ramping up the production of glyphosate, the active ingredient in the weedkiller Roundup that has been accused of causing cancer in scores of lawsuits, including one on appeal to the U.S. Supreme Court.

  • February 19, 2026

    Mylan Investors Ink $60M Deal In Quality Control Suit

    Investors in the former Mylan NV have reached a $60 million settlement with the company over claims the drugmaker manipulated quality control measures at a West Virginia facility and lied to shareholders, the investors told a federal court this week.

  • February 19, 2026

    BakerHostetler Adds Contaminants Pro From DLA Piper

    BakerHostetler announced on Thursday that it has brought a San Francisco-based attorney from DLA Piper onto its product liability and toxic tort and environmental teams, calling him "one of the country's leading emerging contaminants litigators."

Expert Analysis

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For The Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

  • Assessing Compliance Risks Around TrumpRx Participation

    Author Photo

    As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here